On January 11, the "New Non-Toxic Crosslinked Recombinant Collagen Gel for Soft Tissue Wound Repair" project was officially launched at the Changzhou West Taihu Lake Science and Technology Industrial Park. This marks another significant breakthrough in the city’s growing synthetic biology (SynBio) sector.
Part of China’s "14th Five-Year" National Key R&D Program, the project aims to develop advanced diagnostic equipment and biomedical materials. Spearheaded by Changzhou Zhonghui Medical Devices Co., Ltd., in collaboration with the Shanghai Children’s Medical Center, affiliated with Shanghai Jiao Tong University School of Medicine, the project is slated to run until November 2027.
The initiative focuses on addressing the limitations of current animal-derived dermal scaffolds and improving clinical repair outcomes. Researchers are working on developing recombinant collagen-based regenerative materials, along with non-toxic crosslinking technologies, to create a new generation of soft tissue repair materials. The goal is to produce a novel collagen gel with enhanced clinical efficacy, advancing medical treatments for a range of soft tissue injuries.
The project takes a bionic approach to the development of dermal scaffolds, both in terms of material innovation and structural design. It will build on existing recombinant human collagen, with the ultimate goal of commercializing recombinant human collagen and setting new industry standards for bioengineered materials.
Zhonghui Medical, a subsidiary of Jiangsu Trautec Medical Technology Co., Ltd., was established in 2020 and is focused on high-tech innovation in the field of biomaterials. The company specializes in the research, production, and commercialization of medical recombinant collagen products, including absorbable repair dressings and dermal scaffolds. With two registered invention patents, Zhonghui Medical is a national leader in the development of high-bio-mimicry materials and is currently pioneering non-toxic crosslinked composite materials for skin repair.
The National Key R&D Program, China's highest-level research initiative, provides funding for critical projects in areas that affect national security, economic development, and public welfare. It supports cutting-edge research into technologies that will drive China’s global competitiveness and contribute to the overall well-being of its population.
扫一扫在手机打开当前页  |
